Revolution Medicines, Inc. Common Stock (RVMD) is a publicly traded Healthcare sector company. As of November 17, 2026, RVMD trades at $163.79 with a market cap of $36.09B and a P/E ratio of -34.65. RVMD moved -2.53% today. Year to date, RVMD is +107.67%; over the trailing twelve months it is +135.28%. Its 52-week range spans $29.17 to $224.31. Analyst consensus is strong buy with an average price target of $270.04. Rallies surfaces RVMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
EU approves Revolution Medicines’ Rasonque for metastatic pancreatic cancer: The European Commission approved Revolution Medicines’ Rasonque (daraxonrasib) as a once-daily oral monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, regardless of RAS mutation status.
| Metric | Value |
|---|---|
| Price | $163.79 |
| Market Cap | $36.09B |
| P/E Ratio | -34.65 |
| EPS | $-5.95 |
| Dividend Yield | 0.00% |
| 52-Week High | $224.31 |
| 52-Week Low | $29.17 |
| Volume | 1.95M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-1.13B |
| Gross Margin | 0.00% |
24 analysts cover RVMD: 0 strong buy, 23 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $270.04.